Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesA phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma
Cancer, 11/09/09
Hersh EM et al. – nab-Paclitaxel was found to be well tolerated and demonstrated activity in both previously treated and chemotherapy-naive patients with MM. The response rate, PFS, and survival compared favorably with current standard dacarbazine therapy and combination therapies for melanoma.
Methods- Patients with histologically or cytologically confirmed, measurable MM enrolled
- nab-Paclitaxel administered iv weekly for 3 of 4 weeks at dose of 100 mg/m2 (in previously treated patients) or 150 mg/m2 (in chemotherapy-naive patients)
- 37 patients treated in each cohort
- Response rate was 2.7% in previously treated cohort and 21.6% in chemotherapy-naive cohort
- Response plus stable disease rate 37.8% and 48.6% in previously treated and chemotherapy-naive cohorts, respectively
- Median PFS 3.5 months and 4.5 months, and median survival 12.1 months and 9.6 months, respectively
- Probability of being alive and free of disease progression at 6 months 27% for previously treated cohort and 34% for chemotherapy-naive cohort
- Probability of surviving 1 year 49% and 41%, respectively, for previously treated and chemotherapy-naive cohorts
- Approximately 78% of previously treated patients and 49% of chemotherapy-naive patients treated without dose reduction
- 8 (22%) chemotherapy-naive patients discontinued therapy due to toxicities
- Drug-related toxicities included grade 3 to 4 (graded according to National Cancer Institute Common Terminology Criteria for Adverse Events [version 3.0]) neuropathy, alopecia, neutropenia, and fatigue
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma
Medical Oncology, 12/03/09
Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men
Cancer Causes and Control, 12/03/09
Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application
Journal of the European Academy of Dermatology and Venereology, 12/02/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Oleanolic acid derivative Dex-OA has potent anti-tumor and anti-metastatic activity on osteosarcoma cells in vitro and in vivo
Investigational New Drugs, 12/04/09
Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma
BMC Cancer, 12/04/09
Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review
Investigational New Drugs, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor